Form 8-K - Current report:
SEC Accession No. 0001193125-25-023988
Filing Date
2025-02-11
Accepted
2025-02-11 07:38:36
Documents
17
Period of Report
2025-02-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d929959d8k.htm   iXBRL 8-K 25661
2 EX-99.1 d929959dex991.htm EX-99.1 274449
6 GRAPHIC g929959dsp05a.jpg GRAPHIC 14634
7 GRAPHIC g929959dsp05b.jpg GRAPHIC 3566
8 GRAPHIC g929959dsp05c.jpg GRAPHIC 2327
  Complete submission text file 0001193125-25-023988.txt   478121

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rprx-20250211.xsd EX-101.SCH 2857
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rprx-20250211_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rprx-20250211_pre.xml EX-101.PRE 10817
20 EXTRACTED XBRL INSTANCE DOCUMENT d929959d8k_htm.xml XML 3552
Mailing Address 110 EAST 59TH STREET NEW YORK NY 10022
Business Address 110 EAST 59TH STREET NEW YORK NY 10022 (212) 883-0200
Royalty Pharma plc (Filer) CIK: 0001802768 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39329 | Film No.: 25607696
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)